Callan Family Office LLC bought a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 19,924 shares of the company's stock, valued at approximately $264,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in TAK. FMR LLC grew its position in shares of Takeda Pharmaceutical by 10.9% in the third quarter. FMR LLC now owns 2,908,918 shares of the company's stock valued at $41,365,000 after purchasing an additional 286,052 shares during the last quarter. Stifel Financial Corp increased its position in Takeda Pharmaceutical by 103.9% in the 3rd quarter. Stifel Financial Corp now owns 440,666 shares of the company's stock worth $6,266,000 after buying an additional 224,594 shares during the period. Crossmark Global Holdings Inc. lifted its holdings in shares of Takeda Pharmaceutical by 284.9% during the fourth quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company's stock worth $2,787,000 after buying an additional 155,795 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Takeda Pharmaceutical during the fourth quarter worth approximately $1,447,000. Finally, Verition Fund Management LLC bought a new stake in shares of Takeda Pharmaceutical in the third quarter valued at approximately $1,533,000. Institutional investors and hedge funds own 9.17% of the company's stock.
Takeda Pharmaceutical Stock Performance
TAK stock traded down $0.02 on Friday, reaching $15.02. 1,836,545 shares of the company were exchanged, compared to its average volume of 1,801,823. The firm has a market capitalization of $47.78 billion, a PE ratio of 37.54, a PEG ratio of 0.24 and a beta of 0.46. Takeda Pharmaceutical Company Limited has a 12 month low of $12.58 and a 12 month high of $15.22. The stock's fifty day moving average price is $13.73 and its 200 day moving average price is $13.92. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.
Takeda Pharmaceutical Profile
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Featured Articles
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
